$IMUX
Immunic Inc

2019 Q1 Form 10-Q Financial Statement

#000128077619000032 Filed on April 10, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.310M $4.340M $4.590M
YoY Change -69.82% 41.83% 55.07%
% of Gross Profit
Research & Development $3.355M $10.16M $10.19M
YoY Change -66.97% 5.49% 15.01%
% of Gross Profit
Depreciation & Amortization $5.000K $224.0K $220.0K
YoY Change -97.77% -33.13% -46.34%
% of Gross Profit
Operating Expenses $4.662M $2.288M $14.78M
YoY Change 103.76% -81.97% 24.99%
Operating Profit -$4.662M -$14.49M
YoY Change -67.83% 14.23%
Interest Expense $0.00 $170.0K $200.0K
YoY Change -100.0% 70.0% 185.71%
% of Operating Profit
Other Income/Expense, Net $349.0K $104.0K -$10.00K
YoY Change 235.58% 22.35% -150.0%
Pretax Income -$4.310M -$14.39M -$14.59M
YoY Change -70.05% 14.21% 24.38%
Income Tax
% Of Pretax Income
Net Earnings -$4.313M -$2.263M -$14.59M
YoY Change 90.59% -82.04% 24.36%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$576.2K -$13.58M -$13.76M
COMMON SHARES
Basic Shares Outstanding 42.37M shares 42.37M shares 42.21M shares
Diluted Shares Outstanding 43.71M shares

Balance Sheet

Concept 2019 Q1 2018 Q1 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.600M $43.60M $56.90M
YoY Change -77.98% -49.65% -5.17%
Cash & Equivalents $7.593M $43.65M $56.90M
Short-Term Investments
Other Short-Term Assets $400.0K $1.200M $1.200M
YoY Change -66.67% -29.41% -20.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.988M $44.84M $58.12M
YoY Change -77.72% -49.23% -5.44%
LONG-TERM ASSETS
Property, Plant & Equipment $482.0K $2.072M $2.155M
YoY Change -76.74% -16.75% -13.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K $101.0K $108.0K
YoY Change -88.12% -35.26% 86.21%
Total Long-Term Assets $494.0K $2.173M $2.263M
YoY Change -77.27% -17.84% -11.71%
TOTAL ASSETS
Total Short-Term Assets $9.988M $44.84M $58.12M
Total Long-Term Assets $494.0K $2.173M $2.263M
Total Assets $10.48M $47.01M $60.38M
YoY Change -77.7% -48.31% -5.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $184.0K $893.0K $1.049M
YoY Change -79.4% -31.73% 34.49%
Accrued Expenses $1.215M $8.701M $9.141M
YoY Change -86.04% 71.11% 96.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.433M $9.666M $10.28M
YoY Change -85.17% 49.86% 87.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0% 1.01%
Total Long-Term Liabilities $0.00 $47.00K $59.00K
YoY Change -100.0% -31.88% -41.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.433M $9.666M $10.28M
Total Long-Term Liabilities $0.00 $47.00K $59.00K
Total Liabilities $1.433M $9.713M $10.34M
YoY Change -85.25% 49.0% 85.3%
SHAREHOLDERS EQUITY
Retained Earnings -$346.9M -$310.3M -$296.0M
YoY Change 11.78% 21.0% 21.38%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.770M -$15.57M -$13.34M
YoY Change
Total Liabilities & Shareholders Equity $10.48M $47.01M $60.38M
YoY Change -77.7% -48.31% -5.69%

Cashflow Statement

Concept 2019 Q1 2018 Q1 2017 Q4
OPERATING ACTIVITIES
Net Income -$4.313M -$2.263M -$14.59M
YoY Change 90.59% -82.04% 24.36%
Depreciation, Depletion And Amortization $5.000K $224.0K $220.0K
YoY Change -97.77% -33.13% -46.34%
Cash From Operating Activities -$5.317M -$13.07M -$9.920M
YoY Change -59.33% 19.84% 9.01%
INVESTING ACTIVITIES
Capital Expenditures $7.000K $150.0K -$120.0K
YoY Change -95.33% -45.26% 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$7.000K -$150.0K -$110.0K
YoY Change -95.33% -44.44% 10.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $20.53M -$30.00K 540.0K
YoY Change -68536.67% -100.08% -50.91%
NET CHANGE
Cash From Operating Activities -$5.317M -$13.07M -9.920M
Cash From Investing Activities -$7.000K -$150.0K -110.0K
Cash From Financing Activities $20.53M -$30.00K 540.0K
Net Change In Cash $14.95M -$13.25M -9.490M
YoY Change -212.77% -149.73% 17.16%
FREE CASH FLOW
Cash From Operating Activities -$5.317M -$13.07M -$9.920M
Capital Expenditures $7.000K $150.0K -$120.0K
Free Cash Flow -$5.324M -$13.22M -$9.800M
YoY Change -59.74% 18.24% 9.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42369694 shares
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Trading Symbol
TradingSymbol
VTL
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
268000 USD
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
184000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2221000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1215000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10503000 USD
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9801000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
349771000 USD
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
355874000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1553000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6103000 USD
CY2018Q4 us-gaap Assets
Assets
14978000 USD
CY2019Q1 us-gaap Assets
Assets
10482000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
14232000 USD
CY2019Q1 us-gaap Assets Current
AssetsCurrent
9988000 USD
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56901000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43647000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13324000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9595000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13254000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3729000 USD
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9498272 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42368864 shares
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42369694 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42368864 shares
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42369694 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14391000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9493000 USD
CY2019Q1 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
12000 USD
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
22000 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
41000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
224000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
217000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
543000 USD
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
310000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4335000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2690000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-145000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-83000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-441000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1007000 USD
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-31000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-29000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-69000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-553000 USD
CY2019Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1344932 shares
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
170000 USD
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
62000 USD
CY2018Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
89000 USD
CY2019Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14978000 USD
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10482000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2510000 USD
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1433000 USD
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
41000 USD
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13074000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3739000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-14388000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-9493000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
60000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
14492000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
9553000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14492000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9553000 USD
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
33000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12000 USD
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
298000 USD
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
149000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
342000 USD
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
83000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
37000 USD
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12000 USD
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21000 USD
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
34000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 USD
CY2018Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-4000 USD
CY2019Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
CY2018Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
30000 USD
CY2019Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
150000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
908000 USD
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
393000 USD
CY2018Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
CY2019Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
10000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11212000 USD
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10283000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
709000 USD
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
482000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10157000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
494000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337428000 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346909000 USD
CY2018Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
132000 USD
CY2018Q1 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2019Q1 us-gaap Severance Costs1
SeveranceCosts1
6369000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1553000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6103000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.25
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1349075 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.17
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4688646 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.33
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.40
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6183266 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1494620 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.51
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.08
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1478820 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.09
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M23D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y9M7D
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
89000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
50044000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
37295000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
12427000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9049000 USD
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43714626 shares
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42368864 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42369694 shares
CY2018Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
1336000 USD
CY2019Q1 vtl Accrued Clinical Costs
AccruedClinicalCosts
822000 USD
CY2019Q1 vtl Entity Public Float Maximum Amount Equity Issuance Under The Shelf Registration Agreement Would Be Limited
EntityPublicFloatMaximumAmountEquityIssuanceUnderTheShelfRegistrationAgreementWouldBeLimited
75000000 USD
CY2019Q1 vtl Expected Accelerated Allocated Share Based Compensation To Be Recognized
ExpectedAcceleratedAllocatedShareBasedCompensationToBeRecognized
775000 USD
CY2018Q4 vtl Investment Banking Opinion Fees
InvestmentBankingOpinionFees
250000 USD
CY2018Q4 vtl Investment Banking Retainer Fees
InvestmentBankingRetainerFees
75000 USD
CY2018Q4 vtl Investment Banking Transaction Fees
InvestmentBankingTransactionFees
1000000 USD
CY2019Q1 vtl Issuance Of Securities Authorized Offering Amount Under Shelf Registration
IssuanceOfSecuritiesAuthorizedOfferingAmountUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
60000000 USD
CY2018Q2 vtl Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
2500000 shares
CY2019Q1 vtl Operating Lease Liability Increase Decrease Due To Remeasurement Adjustment
OperatingLeaseLiabilityIncreaseDecreaseDueToRemeasurementAdjustment
-1200000 USD
CY2019Q1 vtl Operating Lease Right Of Use Asset Increase Decrease Due To Remeasurement Adjustment
OperatingLeaseRightOfUseAssetIncreaseDecreaseDueToRemeasurementAdjustment
-1200000 USD
CY2019Q1 vtl Reduction In Accrued Clinical Costs Due To Change In Estimate
ReductionInAccruedClinicalCostsDueToChangeInEstimate
429000 USD
CY2019Q1 vtl Reduction In Research And Development Cost Due To Change In Estimate
ReductionInResearchAndDevelopmentCostDueToChangeInEstimate
429000 USD
CY2019Q1 vtl Severance Costs Cash Payment Excluding Tax
SeveranceCostsCashPaymentExcludingTax
540000 USD
CY2019Q1 vtl Severance Costs Consolidated Omnibus Budget Reconciliation Actof1985 Cobra Payments
SeveranceCostsConsolidatedOmnibusBudgetReconciliationActof1985COBRAPayments
35000 USD
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the unaudited interim condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-19-000032-index-headers.html Edgar Link pending
0001280776-19-000032-index.html Edgar Link pending
0001280776-19-000032.txt Edgar Link pending
0001280776-19-000032-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
firstamendmenttoassetpurch.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
secondamendmenttoassetpurc.htm Edgar Link pending
Show.js Edgar Link pending
vtl-033119xexhibit311.htm Edgar Link pending
vtl-033119xexhibit312.htm Edgar Link pending
vtl-033119xexhibit321.htm Edgar Link pending
vtl-033119xexhibit322.htm Edgar Link pending
vtl-20190331.xml Edgar Link completed
vtl-20190331.xsd Edgar Link pending
vtl-20190331_cal.xml Edgar Link unprocessable
vtl-20190331_def.xml Edgar Link unprocessable
vtl-20190331_lab.xml Edgar Link unprocessable
vtl-20190331_pre.xml Edgar Link unprocessable
vtl-33119x10q.htm Edgar Link pending